Mannose-Decorated Solid-Lipid Nanoparticles for Alveolar Macrophage Targeted Delivery of Rifampicin
Pharmaceutics · 20.03.2024 · 16 (3) · 429
DOI: 10.3390/pharmaceutics16030429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 20.03.2024. Verfasst von Hriday Bera und 4 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road No. 103, Shenyang 110016, China. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fellowship of China Postdoctoral Science Foundation, Liaoning Pan Deng Xue Zhe Scholar, Overseas Expertise Introduction Project for Discipline Innovation ("111…, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Alveolar macrophages play a vital role in a variety of lung diseases, including tuberculosis. Thus, alveolar macrophage targeted anti-tubercular drug delivery through nanocarriers could improve its therapeutic response against tuberculosis. The current study aimed at exploring the efficacy of glyceryl monostearate (GMS)-based solid-lipid nanoparticles (SLNs) and their mannose functionalized forms on the alveolar macrophage targeting ability of an anti-tubercular model drug, rifampicin (Rif). Rif-loaded SLNs were accomplished by the solvent diffusion method. These carriers with unimodal particle size distribution (~170 nm) were further surface-modified with mannose via Schiff-base reaction, leading to slight enhancement of particle diameter and a decline of drug loading capacity. The encapsulated Rif, which was molecularly dispersed within the matrices as indicated by their XRD patterns, was eluted in a sustained manner with an initial burst release effect. The uptake efficiency of mannose-modified SLNs was remarkably higher than that of corresponding native forms on murine macrophage Raw 264.7 cells and human lung adenocarcinoma A549 cells. Eventually, the mannose-modified SLNs showed a greater cytotoxicity on Raw 264.7 and A549 cells relative to their unmodified forms. Overall, our study demonstrated that mannose modification of SLNs had an influence on their uptake by alveolar macrophages, which could provide guidance for the future development of alveolar macrophage targeted nanoformulations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road No. 103, Shenyang 110016, China.
- Dr. B. C. Roy College of Pharmacy and Allied Health Sciences, Durgapur 713212, West Bengal, India.
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
ORCID-Profile: Mingshi Yang
Förderung
- National Natural Science Foundation of China
- Fellowship of China Postdoctoral Science Foundation, Liaoning Pan Deng Xue Zhe Scholar, Overseas Expertise Introduction Project for Discipline Innovation ("111…
- China Postdoctoral Science Foundation
- Liaoning Pan Deng Xue Zhe Scholar
- Overseas Expertise Introduction Project for Discipline Innovation
- Guiding Project for Science and Technology of Liaoning Province
- Ministry of Education Chunhui Program
Zitieren
APA
Bera, H., Zhao, C., Tian, X., Cun, D., & Yang, M. (2024). Mannose-Decorated Solid-Lipid Nanoparticles for Alveolar Macrophage Targeted Delivery of Rifampicin. Pharmaceutics, 16(3), 429. https://doi.org/10.3390/pharmaceutics16030429
Vancouver
Bera H, Zhao C, Tian X, Cun D, Yang M. Mannose-Decorated Solid-Lipid Nanoparticles for Alveolar Macrophage Targeted Delivery of Rifampicin. Pharmaceutics. 2024;16(3):429. doi:10.3390/pharmaceutics16030429
BibTeX
@article{Bera2024,
author = {Bera, Hriday and Zhao, Caizhu and Tian, Xidong and Cun, Dongmei and Yang, Mingshi},
title = {Mannose-Decorated Solid-Lipid Nanoparticles for Alveolar Macrophage Targeted Delivery of Rifampicin},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {3},
pages = {429},
doi = {10.3390/pharmaceutics16030429}
}
EUVIMED